Table 2. Multivariate analysis for overall survival (OS) in immune checkpoint blockers (ICBs) alone, ICBs in combination with chemotherapy (CT-ICBs) or CT alone (CT).

Characteristic	ICB OS			CT-ICBs OS			CT OS
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
tUP(log)	0.39	0.21, 0.74	0.004	2.48	0.38, 14.3	0.4	0.70	0.46, 1.06	0.10
PD-L1 TPS	0.98	0.97, 0.99	<0.001	0.99	0.96, 1.01	0.3
Histology (Sq vs nSq)	1.37	0.77, 2.45	0.3	3.94	1.56, 16.8	0.007	0.88	0.47, 1.64	0.7
Smocking (never vs current/former)	1.24	0.56, 2.72	0.6	0.94	0.15, 2.17	0.4	2.12	1.28, 3.52	0.004
ECOG PS (≥2 vs 0–1)	1.81	1.05, 3.13	0.034	0.49	0.29, 8.17	0.6	0.75	0.42, 1.35	0.3
Liver metastasis (yes vs no)	1.14	0.49, 2.64	0.8	1.67	0.82, 12.0	0.093	1.66	1.10, 2.50	0.016
Bone metastasis (yes vs no)	1.15	0.67, 1.97	0.6	3.20	0.60, 6.61	0.3	2.33	1.53, 3.55	<0.001
Brain metastasis (yes vs no)	1.50	0.87, 2.61	0.15	0.35
LDH high vs low	2.36	1.39, 4.01	0.002	2.63	0.94, 1.05	0.8	0.99	0.97, 1.01	0.2
Age	1.01	0.98, 1.03	0.7	0.99	0.45, 14.9	0.3	1.31	0.76, 2.26	0.3
dNLR (>3 vs ≤3)	2.64	0.88, 7.90	0.082	4.75	0.70, 1.87	0.6	1.20	1.00, 1.43	0.049
Number of metastatic sites	0.90	0.72, 1.12	0.3	1.19	0.71, 1.99	0.5	1.10	0.71, 1.71	0.7
Treatment line (second or more vs first)	1.13	0.58, 2.16	0.7

ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; nSq, non-squamous; Sq, squamous; TPS, tumor proportion score; tUP, total number of unique peptide seropositivity